Posted: 8/17/2022 1:33:00 PM
Last Updated:
As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal carcinoma in situ (DCIS). No difference between conventional vs hypofractionated WBI was observed.
Study Details
The open-label trial included 1,608 patients with at least 1 mm of clear radial resection margins after breast-conserving surgery from seven countries in Europe, Australia, New Zealand, Singapore, and Canada. They were randomly assigned between June 2007 and June 2014 to receive WBI with tumor bed boost (n = 803) or no boost (n = 805). A total of 503 patients (category A) were randomly assigned to one of four groups (1:1:1:1) with boost vs no boost after conventional vs hypofractionated WBI. The remaining patients underwent random assignment to boost vs no boost after the involved study centers prespecified use of conventional or hypofractionated WBI. In total, 831 patients received conventional WBI and 777 received hypofractionated WBI. Conventional WBI consisted of 50 Gy in 25 fractions and hypofractionated WBI consisted of 42.5 Gy in 16 fractions. The boost dose was 16 Gy in 8 fractions. The primary endpoint was time to local recurrence.
Local Recurrence
In patients with resected non–low-risk DCIS, a tumor bed boost after WBI reduced local recurrence with an increase in grade 2 or greater toxicity. The results provide the first randomized trial data to support the use of boost radiation after postoperative WBI in these patients to improve local control. The international scale of the study supports the generalizability of the results.
— Chua et al
Tweet this quote
Median follow-up was 6.6 years. Among all patients, the 5-year rate of freedom from local recurrence was 97.1% (95% confidence interval [CI] = 95.6%–98.1%) in the boost group vs 92.7% (95% CI = 90.6%–94.4%) in the no-boost group (hazard ratio [HR] = 0.47, 95% CI = 0.31–0.72, P < .001).
No significant differences in 5-year rates of freedom from local recurrence were observed between conventional vs hypofractionated WBI in the category A group (94.4% vs 93.7%; HR = 0.94, 95% CI = 0.51–1.73, P = .84) or among all randomly assigned patients (94.9% vs 94.9%; HR = 0.94, 95% CI = 0.51–1.74, P = .85); the interaction between tumor bed boost and WBI fractionation was not significant in category A (P = .89) or among all patients (P = .89).
The 5-year rate of freedom from any disease recurrence was 93.7% in the boost group vs 89.6% in the no-boost group (HR = 0.63, 95% CI = 0.46–0.87, P = .0042). No significant differences were observed for conventional vs hypofractionated WBI. Overall survival at 5 years was 99.0% in the boost group vs 98.2% in the no-boost group (HR = 0.81, 95% CI = 0.45–1.45, P = .47).
Adverse Events
Any-grade acute adverse events occurred in 58% of patients in the boost group vs 43% of the no-boost group (grade 3 in 45 vs 23 patients, grade 4 in 2 vs 0 patients). Any-grade late adverse events occurred in 35% vs 24% (grade 3 in 36 vs 32 patients, grade 4 in 5 vs 2 patients). The boost group had higher rates of grade ≥ 2 breast pain (14% vs 10%, P = .003) and induration (14% vs 6%, P < .001). No significant increase in risk of radiation pneumonitis, cardiac disease, or radiation-related second malignancy was observed in the boost group.
The investigators concluded, “In patients with resected non–low-risk DCIS, a tumor bed boost after WBI reduced local recurrence with an increase in grade 2 or greater toxicity. The results provide the first randomized trial data to support the use of boost radiation after postoperative WBI in these patients to improve local control. The international scale of the study supports the generalizability of the results.”
Boon H. Chua, MBBS, of Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Randwick, Australia, is the corresponding author for The Lancet article.
Disclosure: The study was funded by the National Health and Medical Research Council of Australia, Susan G. Komen for the Cure, Breast Cancer Now, OncoSuisse, Dutch Cancer Society, and Canadian Cancer Trials Group. For full disclosures of the study authors, visit thelancet.com.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS & Latest News Update
WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS & More Live News
All this news that I have made and shared for you people, you will like it very much and in it we keep bringing topics for you people like every time so that you keep getting news information like trending topics and you It is our goal to be able to get
all kinds of news without going through us so that we can reach you the latest and best news for free so that you can move ahead further by getting the information of that news together with you. Later on, we will continue
to give information about more today world news update types of latest news through posts on our website so that you always keep moving forward in that news and whatever kind of information will be there, it will definitely be conveyed to you people.
WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS & More News Today
All this news that I have brought up to you or will be the most different and best news that you people are not going to get anywhere, along with the information Trending News, Breaking News, Health News, Science News, Sports News, Entertainment News, Technology News, Business News, World News of this made available to all of you so that you are always connected with the news, stay ahead in the matter and keep getting today news all types of news for free till today so that you can get the news by getting it. Always take two steps forward
Credit Goes To News Website – This Original Content Owner News Website . This Is Not My Content So If You Want To Read Original Content You Can Follow Below Links